(NQ: )

N/A UNCHANGED

Last Price Updated: Add to My Watchlist

Price and Volume

Volume	0
Open	-
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	-
Today's Range	N/A - N/A
52wk Range	N/A - N/A
Shares Outstanding	N/A
Dividend Yield	N/A

Chart for (: )

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

AveXis Reports First Quarter 2018 Financial and Operating Results

May 03, 2018

AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today reported financial...

AveXis Provides Update on Proposed Acquisition by Novartis AG

April 30, 2018

AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced that the...

Performance

More News

AveXis Announces First Patient Dosed in Phase 3 Trial of AVXS-101 in Pre-Symptomatic SMA Types 1, 2 and 3

April 25, 2018

AveXis Presents Initial Data from Pivotal U.S. Trial for SMA Type 1 and 24-Month Follow-Up Data from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology

April 24, 2018

Lifshitz & Miller LLP Announces Investigation of ADT Inc., AveXis, Inc., Connecticut Water Service, Inc., Edge Therapeutics, Inc., Fairmount Santrol Holdings, Inc., Oclaro, Inc., QuinStreet, Inc. and

April 24, 2018

UPDATE 2-Novartis top lawyer exits in wake of Trump attorney deal

May 15, 2018

Notable ETF Inflow Detected - XBI, AVXS, SRPT, ONCE

May 15, 2018

Short Interest Declines 18.3% For AVXS

May 09, 2018

Biotechs Soar After Big Trump Drug Price Speech- Mid-Caps Should Outperform

May 14, 2018

XBI, AVXS, ONCE, SRPT: Large Inflows Detected at ETF

April 26, 2018

BRIEF-AveXis Announces First Patient Dosed In Phase 3 Trial Of AVXS-101 In Pre-Symptomatic SMA Types 1, 2 And 3

April 25, 2018

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.